Compass Therapeutics Furnishes Detailed Phase 2/3 Tovecimig Data, Confirms Late 2026 BLA Submission Plan
CMPX sits 35% above its 52-week low of $1.61 on light trading volume (0.3× avg).
Summary
Compass Therapeutics updated its corporate presentation, providing detailed positive Phase 2/3 clinical data for its lead asset, Tovecimig, and confirming plans for a BLA submission in late 2026.
Key Events · Product Development and Regulatory · CMPX
-
Detailed Phase 2/3 Data for Tovecimig
The corporate presentation includes comprehensive data from the COMPANION-002 study, showing a significant improvement in overall response rate (ORR) of 18.0% versus 5.3% (p=0.0228) and progression-free survival (PFS) of 4.7 months versus 2.6 months (HR=0.44, p<0.0001) for Tovecimig plus paclitaxel in second-line biliary tract cancer.
-
BLA Submission Planned for Late 2026
The company plans to meet with the FDA in Q3 2026 to discuss the data and intends to submit a Biologics License Application (BLA) in late 2026, targeting potential approval in the second half of 2027.
-
OS Data Confounded by Crossover
Overall survival (OS) analysis was confounded by a high crossover rate (54%) from the control arm to the Tovecimig arm, resulting in similar median OS (8.9 vs 9.4 months). However, a post-hoc analysis showed significantly improved OS in crossover patients (12.8 vs 6.1 months).
-
Pipeline Updates and Financial Runway
The presentation also provides updates on other pipeline assets (CTX-8371, CTX-10726, CTX-471) and reiterates a cash runway into 2028 with $195 million in cash and marketable securities at Q1 2026.
Analysis · CMPX · Life Sciences
This filing provides the full corporate presentation detailing the positive Phase 2/3 COMPANION-002 study results for Tovecimig in biliary tract cancer (BTC). The significant improvements in overall response rate (ORR) and progression-free survival (PFS), despite the overall survival (OS) being confounded by patient crossover, solidify the drug's profile. The confirmed plan to submit a Biologics License Application (BLA) in late 2026 is a critical step towards commercialization for the company's lead asset, offering a clear path to potential market entry in 2H 2027.
At the time of this filing, CMPX was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $392.6M. The 52-week trading range was $1.61 to $6.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.